Premium
Screening for fetal aneuploidies at 11 to 13 weeks
Author(s) -
Nicolaides Kypros H.
Publication year - 2011
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.2637
Subject(s) - ductus venosus , fetus , medicine , trisomy , aneuploidy , obstetrics , ultrasound , nuchal translucency , nuchal translucency measurement , pregnancy , pregnancy associated plasma protein a , prenatal diagnosis , gynecology , first trimester , radiology , biology , chromosome , genetics , gene , biochemistry
Effective screening for major aneuploidies can be provided in the first trimester of pregnancy. Screening by a combination of fetal nuchal translucency and maternal serum free‐β‐human chorionic gonadotrophin and pregnancy‐associated plasma protein‐A can identify about 90% of fetuses with trisomy 21 and other major aneuploidies for a false‐positive rate of 5%. Improvement in the performance of first‐trimester screening can be achieved by firstly, inclusion in the ultrasound examination assessment of the nasal bone and flow in the ductus venosus, hepatic artery and across the tricuspid valve, and secondly, carrying out the biochemical test at 9 to 10 weeks and the ultrasound scan at 12 weeks. Copyright © 2011 John Wiley & Sons, Ltd.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom